Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Telitacicept in Sjogren's Disease. The expected timing is based on the latest available company guidance and may change.
8/13/25- Achieved primary endpoint. Late-breaking poster presentation at ACR'25. 10/28/25- Presented 48wk data via webcast. 03/30/26:- First patient dosed in UPSTREAM SjD Phase 3 trial. 05/13/26:- UPSTREAM SjD Ph3 enrollment ongoing in global registrational trial; no topline timing disclosed. 08/11/26:- UPSTREAM MG enrollment ongoing; topline data still anticipated in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.